We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Expression Signature Traces Nonalcoholic Fatty Liver Disease Progression

By LabMedica International staff writers
Posted on 16 Dec 2020
Nonalcoholic fatty liver disease (NAFLD) is a common condition marked by the accumulation of triglycerides and other lipids in the liver and is associated with metabolic syndrome, type 2 diabetes, hypertension, and dyslipidemia. More...


NAFLD can be divided into two subtypes: nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). NAFL can develop into NASH and advanced fibrosis. An expression signature of more than two dozen genes can trace the progression of nonalcoholic fatty liver to nonalcoholic steatohepatitis.

An international team of scientists led by those at Newcastle University (Newcastle upon Tyne, UK) performed RNA-sequencing on liver biopsies from a discovery cohort of 206 patients, 53 with NAFL and 153 with NASH. Unsupervised clustering separated the cohort into two groups, one of which was marked by more advanced fibrosis and included more patients diagnosed with NASH. Nearly 1,300 genes were differentially expressed between the two clusters. They additionally identified more than 2,600 differentially expressed genes between their discovery cohort and a set of healthy obese controls. They also uncovered genes that were differentially expressed between the various stages of NASH progression.

The team translating their findings to the protein level using SomaScan analysis (SomaLogic, Inc, Boulder. CO, USA) and in more than 300 NAFLD serum samples confirmed that circulating concentrations of proteins Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) and Growth/differentiation factor 15 (GDF15) were strongly associated with disease activity and fibrosis stage. The scientists homed in on a set of 25 genes that were associated with progression from NAFL to NASH and to more severe forms of NASH. Using NanoString Technologies’ gene expression platform (Seattle WA, USA), they replicated 21 of the 25 genes in the signature as significantly differentially expressed when comparing different stages of the liver disease in a cohort of 175 patients. This set of genes included several involved in inflammation, retinol metabolism, and Wnt signaling, and they found that many could be induced by endoplasmic reticulum stress.

The team used in vitro functional studies and determined that endoplasmic reticulum stress up-regulated expression of AKR1B10, GDF15, and PDGFA, whereas GDF15 supplementation tempered the inflammatory response in macrophages upon lipid loading and lipopolysaccharide stimulation. They used immunohistochemistry and confirmed that certain markers like AKR1B10, GDF15, and STMN2 were expressed by particular liver cells. AKR1B10, for instance, was more likely to be found in ballooned hepatocytes, and the number of AKR1B10-positive hepatocytes increased with disease stage.

The authors concluded that their transcriptomic data, from a large histologically characterized NAFLD cohort, provide insights into disease pathophysiology, identifying both stable and dynamic differences in gene expression that occur during NAFLD progression. The study was published on December 2, 2020 in the journal Science Translational Medicine.

Related Links:
Newcastle University
SomaLogic, Inc
NanoString Technologies



Gold Member
Serological Pipets
INTEGRA Serological Pipets
Portable Electronic Pipette
Mini 96
New
Blood Glucose Test Strip
AutoSense Test
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.